TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA DURING COVID-19

EHA Library, Evgeniya Paramonova, 357226

DIFFERENCES IN GENE EXPRESSION PATTERN AND IMMUNOPHENOTYPE OF BONE MARROW MULTIPOTENT MESENCHYMAL STROMAL CELLS IN PATIENTS AT THE ONSET OF ACUTE LEUKEMIA AND AFTER ACHIEVING REMISSION

EHA Library, Aleksandra Sadovskaya, 357304

TREATING MULTIPLE MYELOMA IN A RESOURCE-LIMITED SETTING: REAL-WORLD OUTCOMES

EHA Library, Fernanda Seguro, 358881

MULTIPLE MYELOMA AND SPINAL CORD COMPRESSION: THE EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX

EHA Library, Nour Siala, 358882

CLINICAL, LABORATORY PROFILE, TREATMENT AND OUTCOME OF PRIMARY AMYLOIDOSIS IN THE ERA OF NOVEL AGENTS: AN EXPERIENCE FROM A TERTIARY CARE HOSPITAL IN INDIA

EHA Library, Yogalakshmi Sivaprakasam, 358883

CD269, CD319 EXPRESSION ON MALIGNANT PLASMA CELLS AND SOLUBLE BCMA, SLAMF7 PROTEINS COMPARATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Anton Startsev, 358884

MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Rafael Fonseca, 358885

INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Juan Li, 358886

CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Ravi Vij, 358887

CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Sosana Delimpasi, 358888

RISK AND PATTERN OF INFECTIONS IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA VACCINATED UPFRONT AGAINST PNEUMOCOCCUS & INFLUENZA

EHA Library, Arun VA, 358889

RESULTS FROM PIMMS, A UK MYELOMA RESEARCH ALLIANCE (UKMRA) STUDY OF OUTCOMES AND TOXICITY OF PANOBINOSTAT WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MYELOMA IN A REAL WORLD SETTING

EHA Library, Jacken Waters, 358890

LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA

EHA Library, Junling Zhuang, 358891

CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY

EHA Library, Jian Huang, 358892

INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Dragomira Nikolova, 358893

EVALUATION OF THE PROGNOSTIC VALUE OF THROMBOPHILIA MARKERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Tatiana Makarik, 358894

CLINICAL AND MOLECULAR CORRELATION OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A RETROSPECTIVE ANALYSIS FROM A TERTIARY CARE CENTER IN INDIA.

EHA Library, Ramesh B, 358895

ERYTHROCYTOSIS IN PATIENTS WITH TIBETAN EGLN1C127S MUTATION: IS IT A POLYMORPHISM IN PATIENTS LIVING AT SEA LEVEL?

EHA Library, Giacomo Biagetti, 358896

TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)

EHA Library, Federica Irene Grifoni, 358897

POLYCYTHEMIA VERA IN YOUNG SUBJECTS: ABOUT A COHORT OF 11 CASES

EHA Library, Soraya Bougherira, 358898

SHORT-TERM EFFICACY OF DECITABINE IN COMBINATION WITH LOW-DOSE CHEMOTHERAPY IN THE TREATMENT OF JMML: A RETROSPECTIVE STUDY

EHA Library, Yuli Cai, 358899

MOLECULAR DIAGNOSIS OF CONGENITAL ERYTHROCYTOSIS IN A SINGLE HOSPITAL CENTER.

EHA Library, Lucia Castilla, 358900

EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY

EHA Library, Sai Ma, 358901

MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT

EHA Library, José Antonio Delapeña-Celaya, 358902

EVALUATION OF NON-CLONAL ERYTHROCYTOSIS: SINGLE CENTRE EXPERIENCE

EHA Library, Mojca Dreisinger, 358903

PRIMARY MYELOFIBROSIS IN YOUNG PATIENTS ≤50 YEARS: CLINICOPATHOLOGICAL CHARACTERISTICS, GENETIC LANDSCAPE AND DISEASE OUTCOME. A SINGLE CENTER EXPERIENCE

EHA Library, Sarah Elkourashy, 358904

CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.

EHA Library, Sarah Elkourashy, 358905

PRIMARY ARTERIAL HYPERTENSION IN MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW

EHA Library, Mihnea-Alexandru Găman, 358906

HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Hrvoje Holik, 358907

A RARE CASE OF HIGH-RISK HEREDITARY THROMBOPHILIA COMBINED WITH PRIMARY MYELOFIBROSIS

EHA Library, Sviatlana Khoduleva, 358908

MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?

EHA Library, Isabel Montero, 358909

REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION

EHA Library, Adela Perolla, 358910

IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.

EHA Library, S.M.Amine BENLAZAR, 358911

SUCCESSFUL OUTCOME OF A PATIENT WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AZACYTIDINE AND AVAPRITINIB: A CASE REPORT

EHA Library, Chandan Saha, 358912

THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.

EHA Library, Tobias Silzle, 358913

A RARE CASE OF CALR MUTATION IN JAK2-NEGATIVE PATIENT WITH POLYCYTHEMIA

EHA Library, Tatiana Subbotina, 358914

EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN'S LYMPHOMA.

EHA Library, emna bouslama, 358915

CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER

EHA Library, Fatma Kammoun, 358916

RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY

EHA Library, Fatma Kammoun, 358917

IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA

EHA Library, Olga Novosad, 358918

THE STUDY OF GSTP1 AND MDR1 GENES POLYMORPHISMS IN HODGKIN'S LYMPHOMA AND THEIR LINK WITH CHEMOTHERAPY RESPONSE.

EHA Library, Yana Shebunyaeva, 358919

THE REALM STUDY PROTOCOL: A MULTICENTER, NON-INTERVENTIONAL, RETROSPECTIVE STUDY TO DESCRIBE THE TREATMENT PATHWAYS, OUTCOMES, AND RESOURCE USE IN PATIENTS WITH CD30+ LYMPHOMA FROM CHINA.

EHA Library, Jianli Wang, 358920

RETROSPECTIVE ANALYSIS OF HAIRY CELL LEUKEMIA (HCL) PATIENTS (PTS) TREATED WITH DIFFERENT MODALITIES AS FIRST LINE: REAL-LIFE EXPERIENCE OVER 20 YEARS IN KUWAIT.

EHA Library, Ahmad Alhuraiji, 358921

A CASE OF HAIRY CELL LEUKEMIA PRESENTED AS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

EHA Library, Cátia Almeida, 358922

EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.

EHA Library, Carmen Amorós, 358923

INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA

EHA Library, Jose Aspa, 358924

EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA

EHA Library, Abdulkadir Basturk, 358925

LACK OF AGREEMENT ON EVENT-FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA

EHA Library, Côme Bommier, 358926

IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Osman Ilhan, 358927

CRYSTAL STORING HISTIOCYTOSIS PRESENTING AS HEAD AND NECK TUMORS

EHA Library, E. Pedro De, 358928

PEDIATRIC-TYPE FOLLICULAR LYMPHOMA - A NEW PARADIGM IN DIAGNOSIS?

EHA Library, Liliana Fonseca, 358929

POD12 AND POD24 – A NEW SURROGATE MARKER IN MANTLE CELL LYMPHOMA TREATMENT?

EHA Library, José Freitas, 358930

A RETROSPECTIVE ANALYSIS OF THE EFFICACY OF LOW-DOSE METRONOMIC CYCLOPHOSPHAMIDE FOR TREATMENT IN PATIENTS WITH LOW GRADE NON-HODGKIN LYMPHOMA

EHA Library, Boram Han, 358931

INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL

EHA Library, Zengjun Li, 358932

EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA

EHA Library, Jun Ma, 358933

TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS

EHA Library, Christian Buske, 358934

POPULATION-WIDE PATTERNS OF CARE IN MANTLE CELL LYMPHOMA IN AUSTRALIA: AN ANALYSIS OF THE PHARMACEUTICAL BENEFITS SCHEME DATASET

EHA Library, Constantine S. Tam, 358935

STUDY CONDUCT AND PATIENT SAFETY DURING THE COVID-19 PANDEMIC: OBSERVATIONS IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA FROM THE GAZELLE TRIAL OF OBINUTUZUMAB SHORT DURATION INFUSION

EHA Library, Miguel A Canales, 358936

FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.

EHA Library, Olga Mompel, 358937

UPFRONT TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH R-HDAC (RITUXIMAB-HIGH DOSE CYTARABINE + DEXAMETHASONE) IN YOUNG, HIGH RISK PATIENTS IS WELL TOLERATED AND LEADS TO DURABLE RESPONSES.

EHA Library, Georgina U Naylor, 358938

CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS WITH LIVER INFILTRATION

EHA Library, Vladimir Otasevic, 358939

EFFICACY OF A 3RD COVID VACCINE, INCLUDING DURING A BTKI PAUSE, IN INDIVIDUALS WITH WALDENSTRÖM MACROGLOBULINEMIA AND FOLLICULAR LYMPHOMA

EHA Library, Katherine Rankin, 358940

IMMUNE PROFILE OF PATIENTS WITH FOLLICULAR LYMPHOMA ASSESSED BY FLOW CYTOMETRY IN PERIPHERAL BLOOD: CHARACTERISTICS AT DIAGNOSIS AND AT RELAPSE OF THE DISEASE

EHA Library, Andrea Rivero Arango, 358941

ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.

EHA Library, Sergey Kravchenko, 358942

TREATMENT OUTCOME OF ORBITAL MARGINAL ZONE B CELL LYMPHOMA -- TEN YEARS FOLLOW UP IN A SINGLE INSTITUTION

EHA Library, Tran-Der Tan, 358943

INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA

EHA Library, Irene Zamanillo, 358944

PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE

EHA Library, Ghada Abichou, 358945

RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: EXPERIENCE OF A LOW-INCOME CENTER IN TIME OF NEW DRUGS

EHA Library, Maha Charfi, 358946

DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY

EHA Library, Ghada Abichou, 358947

PRIMARY MEDIASTINAL B-CELL LYMPHOMA: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX

EHA Library, Ghada Abichou, 358948

A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA

EHA Library, Carole Soussain, 358949

ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA

EHA Library, Hui Liu, 358950

‘REAL-WORLD' TREATMENT PATTERNS AND PATHWAYS OF SECOND LINE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN UK, CANADA, FRANCE, GERMANY, ITALY AND SPAIN USING A PROSPECTIVE SURVEY OF PHYSICIANS

EHA Library, Sachin Vadgama, 358951

A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

EHA Library, Adam Sharp, 358952

TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE

EHA Library, Evaggelia-Kyriaki Dimitraki, 358953

MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.

EHA Library, Chara Giatra, 358954

PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL

EHA Library, Jean-Marie Michot, 358955

CAN WE ACCURATELY PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA IN THE RITUXIMAB ERA? RETROSPECTIVE COMPARISON OF IPI, AAIPI, R-IPI AND NCCN-IPI

EHA Library, Pedro Chorão, 358956

DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Konstantinos Christofyllakis, 358957

REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.

EHA Library, Mariana Corrochano, 358958

REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2

EHA Library, Adolfo De La Fuente, 358959

CLINICAL MANIFESTATIONS AND EFFICACY ANALYSIS OF 71 CASES OF AIDS-RELATED LYMPHOMA

EHA Library, Jun Liu, 358960

PREVALENCE AND CLINICAL IMPLICATIONS OF CYCLIN D1 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

EHA Library, Xiping Liang, 358961

SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, G. Nowakowski, 358962

PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R‑CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, David Belada, 358963

FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Umberto Vitolo, 358964

MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Richard Greil, 358965

REALMIND: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA STARTING SECOND/THIRD-LINE THERAPY AND NOT RECEIVING A STEM CELL TRANSPLANT

EHA Library, Christopher Flowers, 358966

TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP

EHA Library, Kateryna Filonenko, 358967

TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

EHA Library, Peter Borchmann, 358968

CLINICAL PRESENTATION AND TREATMENT OUTCOME OF CHILDREN WITH B-CELL LYMPHOMA; 3-YEAR STUDY AT CHILDREN'S WELFARE TEACHING HOSPITAL (2016-2018)

EHA Library, Hasanein Ghali, 358969

TEN-YEAR SINGLE CENTER EXPERIENCE TREATING PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: CAN RADIOTHERAPY BE OMITTED?

EHA Library, Inês Gonçalves, 358970

PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)

EHA Library, Mehdi Hamadani, 358971

LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Mehdi Hamadani, 358972

HIV AND MALIGNANT HEMOPATHIES

EHA Library, hajar khibri, 358973

EFFECT OF EDUCATIONAL ACTIVITY ON THE KNOWLEDGE OF CLINICIANS REGARDING THE LATEST CLINICAL TRIAL DATA INVESTIGATING NOVEL EPIGENETIC AGENTS FOR B- AND T-CELL LYMPHOMAS

EHA Library, Victoria Harvey-Jones, 358974

THE EFFICACY OF THE STANDARD AND INTENSIVE CHEMOTHERAPY IN ELDERLY PATIENTS WITH DOUBLE- AND TRIPLE-EXPRESSOR LYMPHOMA.

EHA Library, Mai Fujita, 358975

MANAGEMENT OF PATIENTS WITH CONCOMITANT LIVER CIRRHOSIS AND AGGRESSIVE LYMPHOMA – A LITERATURE REVIEW

EHA Library, Jelena Jelicic, 358976

MYC EXPRESSION ANALYSIS AND PROGNOSIS VALUE IN TRANSFORMED FOLLICULAR LYMPHOMA

EHA Library, Jinhua Liang, 358977

LYMPHOMATOID PAPULOSIS-LIKE (LYP-LIKE) AFTER BRENTUXIMAB VEDOTIN-CHP (BV-CHP) TREATMENT FOR ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)

EHA Library, Patricia Lopez Pereira, 358978